Patheon’s North American president to leave the firm

Peter Bigelow to pursue new opportunities from 1 November

Patheon, a global provider of drug development and manufacturing services, says Peter Bigelow, the firm’s president of its North American operations, will leave the company on 1 November to pursue new opportunities.

‘Patheon has benefited immensely from Peter's leadership and is pleased to announce that Peter has agreed to enter into a consulting relationship with the company for a certain period of time to ensure a smooth transition as we continue to focus on the transformation,’ said Jim Mullen, Patheon's ceo.

Bigelow said: ‘I am very proud of what we have accomplished at Patheon. The North American commercial operations continue to have a strong quality record and focus on customer service and I am proud of everyone's efforts in helping us achieve our number two market position in commercial manufacturing worldwide.’

You may also like

Manufacturing

Financial gains for choosing a single-source outsourcing partner

Tufts Center for Drug Development study shows that there are multimillion-dollar benefits of using single-source pharma drug development and manufacturing model
Design & Build

Patheon to invest $45m to support continued growth

Investments by the pharmaceutical solutions provider include facility and equipment expansions in key service areas to meet growing customer demand
Manufacturing

Anticipating the formulation challenges of complex molecules

Patheon's webinar which took place on 28 June, is now available on demand
Manufacturing

Thermo Fisher Scientific to acquire leading CDMO, Patheon

The transaction represents a purchase price of approximately $7.2bn
Manufacturing

Patheon completes sterile expansion at Greenville site

Company invests $26m in sterile Pharmaceutical Development Services suite
You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing

Technology transfers: reaping rewards, reducing risks

There are a number of strategic advantages that companies can achieve in pharmaceutical production by transferring production between sites
Manufacturing

Patheon named Supply Chain Resiliency Partner of the Year

Patheon N.V., a leading global provider of high-quality drug development and delivery solutions to the pharmaceutical and biopharma sectors, has won the “Supply Chain Resiliency Partner of the Year” award by the Global Supply Chain Resiliency Council
Subscribe now